港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

迈威生物-B

21.940

-0.140-0.63%

成交量：15.34万

成交额：335.01万

市值：98.07亿

市盈率：-7.74

高：22.640

开：22.640

低：21.480

收：22.080

52周最高：31.460

52周最低：20.160

股本：4.47亿

香港流通股本：4,713.02万

量比：0.43

换手率：0.33%

股息：- -

股息率：- -

每股收益(LYR):-2.836

净资产收益率：-118.88%

总资产收益率：-11.80%

市净率：78.68

市盈率(LYR):-7.74

市销率: 11.28

数据加载中...

总览公司新闻资讯公告

迈威生物-B（02493）将于2026年8月30日审议2026年中期业绩

港股午评|恒生指数早盘跌0.63% CRO概念继续走高

迈威生物-B午前涨超13% 两款地舒单抗注射液通过巴西药监机构GMP现场检查

港股异动 | 迈威生物-B(02493.HK)涨超7% 两款地舒单抗注射液通过巴西药监机构GMP现场检查

迈威生物－Ｂ(02493)股价显著下跌11.082%，现价港币$20.22

阿斯达克财经

迈威生物-B发布2026年7月股份变动月报，股本维持稳定

迈威生物(02493.HK)9MW5211注射液临床试验申请获国家药监局批准

阿斯达克财经

迈威生物-B（02493）9MW5211注射液获批开展PBC临床试验

迈威生物-B获批9MW5211原发性胆汁性胆管炎临床试验

迈威生物-B(02493.HK)：9MW5211注射液临床试验申请获得国家药监局批准

迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准

智通财经网

迈威生物－Ｂ(02493)股价下跌5.104%，现价港币$21.94

阿斯达克财经

迈威生物－Ｂ(02493)股价上升5.018%，现价港币$23.44

阿斯达克财经

迈威生物-B：9MW5211注射液白癜风适应症临床试验获国家药监局批准

迈威生物-B(02493)获批开展9MW5211白癜风临床试验

迈威生物：9MW5211注射液临床试验获批适应症为白癜风

活力中国调研行｜探访迈威生物：立足张江科创，直击临床刚需

迈威生物-B（02493）9MW5211注射液获批开展1型糖尿病临床试验

迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准

迈威生物-B 2026年6月股份变动月报表：股本维持不变

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/02493/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":21.94,"timestamp":1787299687045,"preClose":22.08,"halted":0,"volume":153400,"delay":0,"changeRate":-0.006340579710144793,"floatShares":47130200,"shares":447000000,"eps":-2.8355367014561392,"marketStatus":"休市中","change":-0.14,"latestTime":"08-21 16:08:07","open":22.64,"high":22.64,"low":21.48,"amount":3350100,"amplitude":0.052536,"askPrice":21.94,"askSize":200,"bidPrice":21.52,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.7200148358412592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":22.08,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.4322100753151313,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":31.17,"timestamp":1787295600000,"preClose":34.1,"halted":0,"volume":13491800,"delay":0,"premium":"-39.68"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":47130200,"roa":"-11.80%","roe":"-118.88%","lyrEps":-2.835537,"volumeRatio":0.4322100753151313,"shares":447000000,"dividePrice":0,"high":22.64,"amplitude":0.052536,"preClose":22.08,"low":21.48,"week52Low":20.16,"pbRate":"78.68","psRate":"11.28","week52High":31.46,"institutionHeld":0,"latestPrice":21.94,"eps":-2.8355367014561392,"divideRate":0,"volume":153400,"delay":0,"ttmEps":-2.7200148358412592,"open":22.64,"prevYearClose":27.64,"prevWeekClose":23.6,"prevMonthClose":21.02,"prevQuarterClose":23.32,"fiveDayClose":23.6,"twentyDayClose":22,"sixtyDayClose":23.56,"earningDate":1788019200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02493\",params:#limit:5,,,undefined,":[{"date":"2026-08-30","symbol":"02493","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788053400000,"name":null,"time":"","dateTimestamp":1788019200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02493\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02493\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1783699200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02493\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02493","date":"2026-08-21","current":-8.066132,"percent":0.54878,"low":-17.302507,"twenty":-15.760286,"median":-14.849801,"eighty":-13.131915,"high":-12.171256,"avg":-14.6168,"sd":1.34523,"marketCap":15514103639.81},"quantilePoints":[{"date":"2026-04-24","current":-15.289641,"twenty":-16.199622,"median":-15.659552,"eighty":-15.437605,"marketCap":17000217748.15},{"date":"2026-04-30","current":-16.640195,"twenty":-16.379645,"median":-15.593679,"eighty":-15.250239,"marketCap":17562577595.07},{"date":"2026-05-08","current":-16.416983,"twenty":-16.631559,"median":-16.471868,"eighty":-15.350449,"marketCap":17380742435.69},{"date":"2026-05-15","current":-16.009725,"twenty":-16.685787,"median":-16.416983,"eighty":-15.606854,"marketCap":16994157190.87},{"date":"2026-05-22","current":-15.517615,"twenty":-16.631559,"median":-16.0746,"eighty":-15.529829,"marketCap":16434142933.1},{"date":"2026-05-29","current":-14.179755,"twenty":-16.597014,"median":-15.628209,"eighty":-15.240388,"marketCap":15069483633.31},{"date":"2026-06-05","current":-12.517432,"twenty":-16.559668,"median":-15.581594,"eighty":-14.26556,"marketCap":13322161865.15},{"date":"2026-06-12","current":-13.472006,"twenty":-16.526753,"median":-15.469041,"eighty":-13.356302,"marketCap":14328406594.37},{"date":"2026-06-18","current":-12.99766,"twenty":-16.438937,"median":-15.265014,"eighty":-12.92448,"marketCap":13857073336},{"date":"2026-06-26","current":-12.199681,"twenty":-16.378066,"median":-14.95714,"eighty":-12.901569,"marketCap":12942815528.08},{"date":"2026-07-03","current":-14.979824,"twenty":-16.23102,"median":-14.955208,"eighty":-12.918972,"marketCap":15904197681.19},{"date":"2026-07-10","current":-14.849801,"twenty":-16.061625,"median":-14.902504,"eighty":-12.970767,"marketCap":15746801597.92},{"date":"2026-07-17","current":-14.420221,"twenty":-16.08484,"median":-14.955208,"eighty":-13.013901,"marketCap":15345691723.29},{"date":"2026-07-24","current":-14.443737,"twenty":-16.025201,"median":-14.968482,"eighty":-13.071825,"marketCap":15374169818.76},{"date":"2026-07-31","current":-13.354051,"twenty":-15.926439,"median":-14.902504,"eighty":-13.105062,"marketCap":14241292067.7},{"date":"2026-08-07","current":-14.221458,"twenty":-15.744727,"median":-14.562278,"eighty":-13.056126,"marketCap":15195777985.44},{"date":"2026-08-14","current":-15.770582,"twenty":-15.789139,"median":-14.806347,"eighty":-13.105062,"marketCap":16872365889.11},{"date":"2026-08-21","current":-14.469039,"twenty":-15.760286,"median":-14.849801,"eighty":-13.131915,"marketCap":15514103639.81}],"updateTime":1787454351215},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02493\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150815623","title":"迈威生物-B（02493）将于2026年8月30日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1150815623","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150815623?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 16:42","pubTimestamp":1787128925,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”或“公司”）公告称，公司董事会已排期于2026年8月30日召开会议，审议并通过集团截至2026年6月30日止六个月的中期业绩，并处理其他事项。\n根据公告，目前公司董事会成员包括：执行董事唐春山、董事长兼执行董事刘大涛、执行董事武海、执行董事华俊、执行董事桂勋；独立非执行董事秦正余、周睿、李凡及王芳。\n公告强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并对其准确性或完整性不作任何声明。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969219?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1183","BK1587","BK1588","LU1504937902.USD","HSI","LU0328353924.USD","LU0329678337.USD","LU1242518931.SGD","LU2264538146.SGD","BK1191","09067","LU2008162690.USD","BK1129","HSTECH","LU0048580855.USD","BK1576","HK0000320264.USD","LU0049853897.USD","LU0164880469.USD","LU0634319403.HKD","BK1198","LU0061477393.USD","PONY","BK1505","06951","03067","LU0509642566.USD","06821","688234","06616","LU0348735423.USD","LU1808992512.USD","LU1242518857.USD","LU1988902786.USD","LU0886674414.USD","513600","LU2039709279.SGD","BK1594","BK1190","LU1770034418.SGD","LU0266512127.USD","LU0287142896.SGD","03759","LU1831875114.USD","LU0345780281.USD","LU2460026573.USD","LU2097828714.EUR","LU0211977185.USD","LU2097828631.EUR","HK0000320223.HKD","01548","03417","82800","JINFF","MCHmain","LU0828238088.HKD","LU0918141887.USD","LU1794554557.SGD","BK1169","LU0348766576.USD","BK1544","03423","LU0561508036.HKD","LU0348825331.USD","03088","LU0082770016.USD","LU1188198961.HKD","LU0164865239.USD","LU0348814723.USD","LU1481107354.HKD","07552","09088","LU2488822045.USD","LU1769817179.HKD","BK1574","LU0821914370.USD","LU0278937759.USD","LU0269904917.USD","HK0000306701.USD","LU0327786744.USD","LU0348827113.USD","07500","LU0918141705.HKD","LU0348816934.USD","LU0417516902.SGD","LU3063872942.SGD","01651","02899","BK1141","601899","LU0540923850.HKD","LU0431992006.USD","03419","300759","LU1048596156.SGD","LU1224709979.USD","LU1251922891.USD","LU0348767384.USD","BK1109","LU0463099449.HKD","LU2226246903.HKD","LU0096374516.USD","LU0181495838.USD","LU0737861772.HKD","LU0140636845.USD","LU0797268264.HKD","09688","LU1064131342.USD","LU0329678170.USD","LU0244354667.USD","IE0032431581.USD","LU0979878070.USD","07226","03037","LU0043850808.USD","LU0868486357.SGD","LU1961090484.USD","LU0173614495.USD","300408","LU1303224171.USD","SG9999002463.SGD","BK1170","02026","LU0266512473.USD","LU0828237940.HKD","LU2097828557.USD","LU0082770016.SGD","LU0620787316.HKD","LU0531971595.HKD","HK0000306685.HKD","02837","07200","LU1720050803.USD","LU1719994722.HKD","LU0588546209.SGD","03115","07300","02099","SG9999003461.SGD","02493","LU0106959298.USD","LU0469268626.HKD","03032","688062","LU0307460666.USD","LU0345780521.USD","02800","LU2399975544.HKD","002821","LU0370786039.SGD","LU0106252389.USD","LU0828237510.HKD","02631","BK1592","09115","LU0228659784.USD","02833","LU0149721374.USD","LU0456854461.SGD","ZIJMY","LU0871576103.HKD","ZLAB","LU0737861699.HKD","LU0274383008.USD","LU0417516738.SGD","LU1105468828.SGD","LU0165289439.USD","LU2097828805.USD","LU1769817096.USD","SG9999004220.SGD","BK1583","HHImain","01541","LU0039217434.USD","LU2177674079.SGD","83115","BK1161","LU0164939612.USD","LU0572944931.SGD","LU2097828474.EUR","LU0326950275.SGD","SG9999001093.SGD","03033","LU1282648689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969469","title":"迈威生物-B午前涨超13% 两款地舒单抗注射液通过巴西药监机构GMP现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969469","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969469?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 11:55","pubTimestamp":1786420500,"startTime":"0","endTime":"0","summary":"模拟交易客户端迈威生物-B盘中涨超13%，截至发稿，股价上涨11.38%，现报25.06港元，成交额3301.81万港元。据迈威生物官微消息，近日，公司宣布其全资子公司泰康生物已顺利通过巴西国家卫生监督局针对两款地舒单抗注射液9MW0311和9MW0321的GMP现场检查。这也是迈威生物继约旦之后再次获得PIC/S成员国药监机构颁发的GMP证书。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-11/doc-inimxewp0810070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159100","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966159","title":"港股异动 | 迈威生物-B(02493.HK)涨超7% 两款地舒单抗注射液通过巴西药监机构GMP现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658966159?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 10:49","pubTimestamp":1786416560,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604702","title":"迈威生物－Ｂ(02493)股价显著下跌11.082%，现价港币$20.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604702","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658604702?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 11:43","pubTimestamp":1786333380,"startTime":"0","endTime":"0","summary":"[下跌股]迈威生物－Ｂ(02493) 股价在上午11:43比前收市价显著下跌11.082%，现股价为港币$20.22。至目前为止，今日最高价为$23.78，而最低价为$20.22。总成交量为7万股，总成交金额为港币$161.36万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608101299/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608101299/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149722085","title":"迈威生物-B发布2026年7月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149722085","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149722085?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 16:51","pubTimestamp":1786006272,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年8月6日披露截至2026年7月31日的证券变动月报表，报告期内公司股本结构保持稳定。公司月报显示，迈威生物-B于报告期末的法定/注册股本总额为人民币446,730,200元，与上月末持平。截至2026年7月31日，迈威生物-B H股已发行股份总数为47,130,200股，均为流通股，无库存股份；A股总计399,600,000股，其中398,407,631股已上市流通，1,192,369股为库存股份，与上月末相比均无增减变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656344742","title":"迈威生物(02493.HK)9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656344742","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656344742?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 10:35","pubTimestamp":1785724500,"startTime":"0","endTime":"0","summary":"迈威生物-B(02493.HK) 公布，收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于原发性胆汁性胆管炎(PBC)适应症的临床试验申请获得批准。此前，其用于炎症性肠病(IBD)适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化(MS)、1型糖尿病(T1DM)和白癜风适应症的临床试验申请已获得国家药品监督管理局批准；公司亦在积极推进其他适应症临床试验申请工作。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260420093816116_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260420093816116_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536166/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536166/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187358293","title":"迈威生物-B（02493）9MW5211注射液获批开展PBC临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187358293","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187358293?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 20:15","pubTimestamp":1785500127,"startTime":"0","endTime":"0","summary":"7月31日，迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”）公布，其自主研发的9MW5211注射液用于原发性胆汁性胆管炎（PBC）适应症的临床试验申请已获国家药品监督管理局（NMPA）批准。该试验的《药物临床试验批准通知书》编号为2026LP023302，NMPA于2026年5月26日受理该申请并作出同意开展临床试验的审评结论。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151666563","title":"迈威生物-B获批9MW5211原发性胆汁性胆管炎临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151666563","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151666563?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 20:12","pubTimestamp":1785499943,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司7月31日在港交所披露海外监管公告称，公司已于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准其自主研发的9MW5211注射液开展用于原发性胆汁性胆管炎适应症的境内临床试验。9MW5211是一款高度特异性的清除型创新抗体，针对自身免疫性疾病中由异常免疫细胞介导的关键病理机制进行精准干预。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655668573","title":"迈威生物-B(02493.HK)：9MW5211注射液临床试验申请获得国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655668573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655668573?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 20:07","pubTimestamp":1785499632,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655352703","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655352703","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655352703?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 18:08","pubTimestamp":1785492492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于原发性胆汁性胆管炎适应症的临床试验申请获得批准，此前，其用于炎症性肠病适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化、1型糖尿病和白癜风适应症的临床试验申请已获得国家药品监督管理局批准;公司亦在积极推进其他适应症临床试验申请工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IBBJ","688062","MDTX","BMED","02493","PSYK","IBBQ","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653570937","title":"迈威生物－Ｂ(02493)股价下跌5.104%，现价港币$21.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2653570937","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653570937?lang=zh_cn&edition=fundamental","pubTime":"2026-07-24 13:45","pubTimestamp":1784871900,"startTime":"0","endTime":"0","summary":"[下跌股]迈威生物－Ｂ(02493) 股价在下午01:44比前收市价下跌5.104%，现股价为港币$21.94。至目前为止，今日最高价为$23.8，而最低价为$21.94。总成交量为24.32万股，总成交金额为港币$545.059万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607242468/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607242468/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652609592","title":"迈威生物－Ｂ(02493)股价上升5.018%，现价港币$23.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2652609592","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652609592?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 14:20","pubTimestamp":1784528400,"startTime":"0","endTime":"0","summary":"[上升股]迈威生物－Ｂ(02493) 股价在下午02:20比前收市价上升5.018%，现股价为港币$23.44。至目前为止，今日最高价为$24.22，而最低价为$21.9。总成交量为25.02万股，总成交金额为港币$583.593万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2607207618/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2607207618/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145126713","title":"迈威生物-B：9MW5211注射液白癜风适应症临床试验获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1145126713","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145126713?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 20:13","pubTimestamp":1784117584,"startTime":"0","endTime":"0","summary":"2026年7月15日，迈威（上海）生物科技股份有限公司发布自愿性公告称，其自主研发的9MW5211注射液用于白癜风适应症的临床试验申请已获国家药品监督管理局批准。公告显示，9MW5211注射液境内生产药品注册临床试验申请编号为2026LP021512。该申请于2026年5月11日受理，经审评符合药品注册相关要求，同意开展白癜风临床试验。9MW5211是一种高度特异性的清除型创新抗体，靶向在致病性免疫细胞表面特异性表达的分子，以精确清除病理性免疫细胞、阻断免疫级联反应。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198929758","title":"迈威生物-B(02493)获批开展9MW5211白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198929758","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198929758?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 20:00","pubTimestamp":1784116834,"startTime":"0","endTime":"0","summary":"2026年7月16日，迈威（上海）生物科技股份有限公司公告，其自主研发的9MW5211注射液针对白癜风的临床试验申请获国家药品监督管理局核准签发《药物临床试验批准通知书》。根据审批结论，监管机构同意公司在境内开展9MW5211注射液用于白癜风适应症的临床试验。公告显示，9MW5211为公司自主研发的清除型创新抗体，靶向自身免疫疾病中由异常免疫细胞介导的关键病理机制。公司将按照规定及时披露项目进展信息，投资者需注意投资风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651570494","title":"迈威生物：9MW5211注射液临床试验获批 适应症为白癜风","url":"https://stock-news.laohu8.com/highlight/detail?id=2651570494","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651570494?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 19:10","pubTimestamp":1784113800,"startTime":"0","endTime":"0","summary":"7月15日，迈威生物（688062/02493）发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于白癜风适应症的临床试验申请获得批准。此前，该药物已获得针对炎症性肠病（IBD）、多发性硬化（MS）和1型糖尿病（T1DM）适应症的临床试验申请批准。2026年一季度，迈威生物实现收入1.28亿元，归母净利润-2.42亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807630914.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807630914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BMED","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996456","title":"活力中国调研行｜探访迈威生物：立足张江科创，直击临床刚需","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996456","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996456?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 20:41","pubTimestamp":1783514463,"startTime":"0","endTime":"0","summary":"7月8日，记者跟随“2026年活力中国调研行”主题采访活动走进张江创新药企业迈威生物，实地探访企业从基础靶点发现、前沿技术开发到临床转化落地的全链条创新体系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798618939.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798618939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","159982","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100315193","title":"迈威生物-B（02493）9MW5211注射液获批开展1型糖尿病临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1100315193","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100315193?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 21:08","pubTimestamp":1783429712,"startTime":"0","endTime":"0","summary":"7月7日，迈威生物-B公告称，其自主研发的创新抗体药物9MW5211注射液针对1型糖尿病的临床试验申请获国家药品监督管理局批准，临床试验通知书编号为2026LP020092，受理日期为2026年4月27日。公司表示，9MW5211此前已获准在炎症性肠病及多发性硬化等适应症开展临床试验，其中IBD适应症已分别获得NMPA批准及美国食品药品监督管理局许可。迈威生物表示，将依据监管要求及时披露项目后续进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987609","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987609?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 20:15","pubTimestamp":1783426507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于1型糖尿病适应症的临床试验申请获得批准，此前，其用于炎症性肠病适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化适应症的临床试验申请已获得国家药品监督管理局批准。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","02493","BK1161","688062","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188352203","title":"迈威生物-B 2026年6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1188352203","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188352203?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 16:52","pubTimestamp":1783414328,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年7月7日发布了《股份变动月报表》，报告期为2026年6月。月报显示，公司在本月内未发生新的股份发行、回购或注销等变动，整体股本保持稳定。本月底公司法定注册股本合计达到人民币446,730,200元。两类股份在报告期内均无新增发行或减少情形，总股本维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":86,"code":"91000000","status":"200"}]}}